drugset / Trial / NCT01978561

Follow-Up Of Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)

NCT01978561 ↗

Phase 2 Completed 40 enrolled Nora Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to evaluate pregnancy, delivery, and neonatal outcomes in subjects who maintain ongoing clinical pregnancies through Week 10 of gestation in NT-03.

Timeline

Start
2013-10
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NT100 Unknown — —